ClinicalTrials.gg
RecruitingNCT06179069Updated Oct 16, 2026

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

A Phase 1 interventional study of ZL-1310 and Atezolizumab in SCLC, sponsored by Zai Lab (Shanghai) Co., Ltd.. Recruiting at 41 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Oct 16, 2026First site in Israel3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
339
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Read the detailed description

This is an open-label, ascending, multiple-dose, phase 1 study evaluating ZL-1310 as a single agent, in combination with Atezolizumab, and in combination with Atezolizumab and Carboplatin in subjects with extensive SCLC.

02

Conditions studied

  • SCLC
03

In context

Lead sponsor

Zai Lab (Shanghai) Co., Ltd. is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Participant with or extensive-stage small cell lung cancer (de novo, not transformed) and for Part 1A and 1B must have documented disease progression during or following a platinum-based chemotherapy regimen. For Part 1C and Part 4, no prior systemic treatment for SCLC (including chemoradiotherapy for limited-stage SCLC). For Part 1B backfill and Part 3, setting: no prior systemic treatment for SCLC (including chemoradiotherapy for limited-stage SCLC); or, first-line maintenance setting: participants have received at least 4 cycles of 1L induction therapy with carboplatin or cisplatin, etoposide, and inhibitor for ES-SCLC with ongoing CR, PR, or SD per v1.1 assessed by the investigator. For Part 2-1, participants must have received no more than 2 lines of prior therapies in the extensive-stage setting, and progressed on or after a platinum-based chemotherapy regimen AND an anti-DLL3 T-cell engager (TCE). For Part 3, participants have received at least 4 cycles of 1L induction therapy with carboplatin or cisplatin etoposide, and anti-PD-L1 inhibitor for ES-SCLC with ongoing CR, PR, or SD per RECIST v1.1 assessed by the investigator.
  • Adult men and women ≥18 years of age.
  • (ECOG) performance status of 0 or 1.
  • Subjects must have at least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
  • Subjects must be willing to undergo a tumor or must provide archived tumor tissue sample at screening per protocol guidelines.
  • >/= 3 months.

Exclusion criteria

Exclusion Criteria:

  • Participants with another known that is progressing or requires active treatment within the last 2 years. Exceptions: basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin with previously administered curative treatment, in situ cervical cancer, or other cancers that do not require systemic anti-cancer therapies and will not impact .
  • Symptomatic or untreated requiring concurrent treatment. For Part 2, Part 3, and Part 4 the following subjects can be enrolled if they have a stable neurologic status for at least 2 weeks prior to the first dose of ZL-1310:

    1. Subjects with untreated and asymptomatic brain metastases.
    2. Subjects with treated brain metastases that are no longer symptomatic (i.e. without neurologic signs or symptoms), who require no treatment with steriods or anticonvulsants and have recovered from the actue toxic effects of radiotherapy.
  • Subjects with .
  • Treatment with any systemic anti-cancer treatment or other products/ device within 3 weeks before first dose of study treatment.
  • Non-palliative radiotherapy within 2 weeks prior to first dose of study treatment or have had a history of radiation pneumonitis.
  • Major surgery within 4 weeks of the first dose of study treatment.
  • to any ingredient of the study treatment.
  • Inadequate organ function (as defined in protocol) within 10 days prior to the first dose of study treatment,
  • Participants with a diagnosis of immunodeficiency or receiving chronic systemic therapy or any other form of therapy within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer.
  • Participants have received a live or within 30 days of planned start of study therapy.
  • Impaired cardiac function or cardiac disease within the last 3 months before administration of the first dose of the study treatment
  • Lung-specific intercurrent clinically significant illnesses and any , connective tissue, or inflammatory disorders, including but not limited to pneumonitis.
  • Pregnant or nursing (lactating) women.
  • Participants who have been on concomitant strong or CYP2D6 inhibitors within 14 days or 5 half-lives before the first study treatment, whichever is longer.
  • For Part 1C and Part 4 (ZL-1310 in combination with Atezolizumab and Carboplatin), participants who received prior treatment with CD137 agonists or immune checkpoint blockade therapies, , and anti-PD-L1 therapeutic antibodies.
  • For Part 1B (ZL-1310 in combination with Atezolizumab) and Part 1C (ZL-1310 in combination with Atezolizumab and Carboplatin), participants who received systemic immunostimulatory agents (including but not limited to, IFNs and IL2) within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to the initiation of study treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
339 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: Part 1A

    ZL-1310 as a single-agent

    Drug: ZL-1310

  • Experimental
    Dose Expansion: Part 1B

    ZL-1310 in combination with Atezolizumab

    Drug: ZL-1310 · Drug: Atezolizumab

  • Experimental
    Dose Escalation: Part 1C

    ZL-1310 in combination with Atezolizumab and Carboplatin as induction and followed by ZL-1310 and Atezolizumab as maintenance

    Drug: ZL-1310 · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Dose Expansion: Arm 1 (Part 2)

    Dose level 1 of ZL-1310 established from single-agent dose-escalation

    Drug: ZL-1310

  • Experimental
    Dose Expansion: Arm 2 (Part 2)

    Dose level 2 of ZL-1310 established from single-agent dose escalation

    Drug: ZL-1310

  • Experimental
    Dose Extension: Arm 1 (Part 2)

    ZL-1310 as a single agent

    Drug: ZL-1310

  • Experimental
    Doublet Dose Optimization: Arm 1 (Part 3A)

    Dose level 1 of ZL-1310 established from single agent dose escalation, in combination with Atezolizumab

    Drug: ZL-1310 · Drug: Atezolizumab

  • Experimental
    Doublet Dose Optimization: Arm 2 (Part 3A)

    Dose level 2 of ZL-1310 established from single agent dose escalation in combination with Atezolizumab

    Drug: ZL-1310 · Drug: Atezolizumab

  • Experimental
    Triplet Dose Optimization: Arm 1 (Part 4A)

    Dose level 1 of ZL-1310 established from single agent dose escalation in combination with Atezolizumab + Carboplatin induction followed by ZL-1310 + Atezolizumab as maintenance

    Drug: ZL-1310 · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Triplet Dose Optimization: Arm 2 (Part 4A)

    Dose level 2 of ZL-1310 established from single agent dose escalation, in combination with Atezolizumab + Carboplatin induction followed by ZL-1310 + atezolizumab as induction

    Drug: ZL-1310 · Drug: Atezolizumab · Drug: Carboplatin

  • Experimental
    Dose Extension: Part 2-1

    single-agent dose extension for Post-anti-DLL3

    Drug: ZL-1310

  • Experimental
    Doublet Dose Extension: Part 3B

    Doublet dose extension for 1L maintenance only OR 1L induction + maintenance; to be initiated at the discretion of the sponsor based on the available emerging data.

    Drug: ZL-1310 · Drug: Atezolizumab

  • Experimental
    Triplet Dose Extension: Part 4B

    Triplet dose extension for 1L induction + maintenance; to be initiated at the discretion of the sponsor based on the available emerging data.

    Drug: ZL-1310 · Drug: Atezolizumab · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)

    Number of subjects with Dose Limiting Toxicities (DLTs)

    Time frame: up to 24 months

  2. Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)

    Number of subjects with treatment-emergent adverse events (TEAEs)

    Time frame: up to 24 months

  3. Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)

    Number of subjects with serious adverse events

    Time frame: up to 24 months

  4. Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)

    Number of subjects with treatment emergent adverse events leading to dose modifications and/or study treatment discontinuation

    Time frame: up to 24 months

  5. Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)

    Number of subjects with serious adverse events

    Time frame: up to 24 months

  6. Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)

    antitumor activity per RECIST v1.1 by investigator's assessment

    Time frame: up to 24 months

  7. Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)

    objective response rate per RECIST v1.1

    Time frame: up to 24 months

  8. Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumab

    disease control rate per RECIST v1.1

    Time frame: up to 24 months

Secondary outcomes

  1. Objective response rate (ORR) per RECIST 1.1 of ZL-1310 as a single agent (Part 1A) in combination with atezolizumab (Part 1B), in combination with atezolizumab and carboplatin (Part 1C, Part 3)

    Objective Response Rate (ORR) per RECIST 1.1

    Time frame: up to 24 months

  2. Disease control rate (DCR) per RECIST v1.1 of ZL-1310 as a single agent (Part 1A and Part 2), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 4)

    Disease control rate (DCR) per RECIST v1.1

    Time frame: up to 24 months

  3. Duration of response per RECIST v1.1

    Duration of response per RECIST v1.1

    Time frame: up to 24 months

  4. Progression free survival per RECIST v1.1

    Progression free survival per RECIST v1.1

    Time frame: up to 24 months

  5. Overall Survival of ZL-1310

    Overall Survival of ZL-1310

    Time frame: up to 24 months

  6. Pharmacokinetics: Total Antibody of ZL-1310

    Pharmacokinetics: Total Antibody of ZL-1310

    Time frame: up to 24 months

  7. Pharmacokinetics: Unconjugated payloads of ZL-1310

    Pharmacokinetics: Unconjugated payloads of ZL-1310

    Time frame: up to 24 months

07

Study locations

32 of 41 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for May 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 21, 2023
StartActual
Jan 23, 2024
Primary completionEst.
May 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in Israel
Show 3 added (3 Israel)
  • Rabin Medical Center · Petah Tikva, Israel
  • The Chaim Sheba Medical Center · Ramat Gan, Israel
  • Tel Aviv Sourasky Medical Center Ichilov · Tel Aviv, Israel
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    3 sites added — first site in Israel
    Show 3 added (3 Israel)
    • Rabin Medical Center · Petah Tikva, Israel
    • The Chaim Sheba Medical Center · Ramat Gan, Israel
    • Tel Aviv Sourasky Medical Center Ichilov · Tel Aviv, Israel

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06179069
Collaborators
Zai Lab (US) LLC
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Jan 23, 2024
Primary completion
May 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Erin Nurre
Contact
Study-ZL-1310-001@zailaboratory.com
6503601601
Mona Qureshi
Contact
Study-ZL-1310-001@zailaboratory.com
6503601601

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zocilurtatug Pelitecan

Start the discussion